LRRC2 Inhibitors
LRRC2 Inhibitors comprise a range of chemical compounds that impede the functional activity of LRRC2 by targeting specific signaling pathways that intersect with LRRC2 regulation or activity. Compounds such as PIK-75 and LY 294002 exert their inhibitory effects by disrupting the PI3K/Akt pathway, which plays a crucial role in cell survival and proliferation, and their actions can lead to the diminishment of LRRC2 activity. Similarly, PD 98059 and U0126 inhibit the MAPK/ERK pathway, a vital signaling mechanism that may have regulatory effects on LRRC2. SB 203580 and SP600125 target the p38 MAPK and JNK pathways, respectively, potentially mitigating stress-related cellular responses and signaling events that stabilize LRRC2. The specific inhibition of the NF-kappaB pathway by BMS-345541 could indirectly influence LRRC2 function by altering inflammatory responses within the cell.
Additionally, the mTOR pathway, which is involved in processes such as cell growth and autophagy, is targeted by Rapamycin, potentially affecting LRRC2-related pathways. WZ4003, as a NUAK1 inhibitor, could lead to alterations in cellular metabolism and stress responses, influencing LRRC2 functions. Gefitinib's role in blocking EGFR signaling also contributes to the inhibition landscape by potentially affecting downstream pathways that modulate LRRC2 activity. The Rho/ROCK pathway, implicated in cytoskeletal dynamics, is disrupted by Y-27632, which could indirectly lead to the functional inhibition of LRRC2 through changes in cell structure and motility. Lastly, Gö 6983's inhibition of PKC-mediated signaling further diversifies the mechanisms through which LRRC2 activity can be diminished, highlighting the complexity and interconnectivity of cellular pathways that govern the function of LRRC2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PIK-75, hydrochloride | 372196-77-5 | sc-296089 sc-296089A | 1 mg 5 mg | $29.00 $124.00 | ||
PIK-75 is a potent inhibitor of phosphoinositide 3-kinase (PI3K) alpha. By inhibiting PI3K alpha, PIK-75 can reduce the PI3K/Akt signaling pathway, which when overactive, is known to negatively regulate LRRC2 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that interferes with the MAPK/ERK pathway. This inhibition can lead to decreased ERK signaling which is implicated in the regulation of a variety of cellular processes, potentially including those involving LRRC2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor that can suppress the p38 MAPK pathway, which may be involved in cellular stress responses that modulate LRRC2 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that impairs the PI3K/Akt pathway, which could affect cell survival and proliferation signals, ultimately diminishing the functional activity of LRRC2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK signaling pathway. By inhibiting JNK, it could disrupt signaling events that either stabilize or enhance the function of LRRC2, thereby leading to its functional inhibition. | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $312.00 | 1 | |
BMS-345541 selectively inhibits the NF-kappaB pathway by targeting IKK. This could disrupt cellular inflammation responses that may indirectly involve the regulation or activity of LRRC2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress the mTOR signaling pathway, potentially affecting processes such as cell growth and autophagy that could intersect with LRRC2 function. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
WZ4003 is a selective NUAK1 inhibitor that disrupts the LKB1-NUAK1 pathway. Inhibition of this pathway could lead to alterations in cellular metabolism and stress responses, which may affect the functional activity of LRRC2. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor that blocks EGFR signaling. Inhibition of EGFR could lead to downstream effects on cellular pathways that modulate the functional activity of LRRC2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are components of the MAPK/ERK pathway. By inhibiting this pathway, U0126 could indirectly lead to decreased functional activity of LRRC2 by affecting its regulatory mechanisms. | ||||||